...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Molecular Biosciences >Analyzing and Validating the Prognostic Value of a TNF-Related Signature in Kidney Renal Clear Cell Carcinoma
【24h】

Analyzing and Validating the Prognostic Value of a TNF-Related Signature in Kidney Renal Clear Cell Carcinoma

机译：肾肾透明细胞癌TNF相关签名的预后价值分析与验证

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Kidney renal clear cell carcinoma (KIRC) has the highest incidence rate in renal cell carcinoma (RCC). Although bioinformatics is widely used in cancer, few reliable biomarkers of KIRC have been found. Therefore, continued efforts are required to elucidate the potential mechanism of the biogenesis and progression of KIRC. Methods: We evaluated the expression of tumor necrosis factor (TNF) family genes in KIRC, and constructed a prognostic signature. We validated the signature by another database and explored the relationship between the signature and progression of KIRC. We assessed the prognostic value, immune infiltration, and tumor mutation burden (TMB) of the signature in KIRC. Results: We selected four key genes (TNFSF14, TNFRSF19, TNFRSF21, and EDA) to construct the TNF-related signature. we divided the KIRC patients into high-risk and low-risk groups based on the signature. Patients with higher risk scores had shorter overall survival and worse prognosis. With another database, we validated the value of the signature and it was considered as an independent risk factor. A higher level of risk score was relevant to higher level of immune infiltration, especially T regulatory cells, CD8 T cells, and macrophages. The signature was also associated with TMB scores, and it may have an effect on assessing the efficacy of immunotherapy. Conclusions: This is the first TNF-family-related signature of KIRC and we demonstrated its effectiveness. It played a significant role in predicting the prognosis of patients with KIRC. It also has the potential to become a powerful tool in guiding the immunotherapy of KIRC patients in clinical practice.
机译：背景：肾脏肾透明细胞癌（KIRC）具有肾细胞癌（RCC）发病率最高。虽然生物信息学广泛用于癌症，但已经发现了很少有kirc的可靠生物标志物。因此，需要持续的努力来阐明生物发生和kirc进展的潜在机制。方法：评估kirc中肿瘤坏死因子（TNF）家族基因的表达，并构建了预后签名。我们通过另一个数据库验证了签名，并探讨了KIRC签名与进展之间的关系。我们评估了kirc签名的预后价值，免疫浸润和肿瘤突变负担（TMB）。结果：我们选择了四个关键基因（TNFSF14，TNFRSF19，TNFRSF21和EDA），构建与TNF相关的签名。根据签名，我们将kirc患者分为高风险和低风险群体。风险评分较高的患者较短，总生存率较短，预后更差。通过另一个数据库，我们验证了签名的价值，它被认为是一个独立的风险因素。较高水平的风险评分与较高水平的免疫浸润，特别是T调节细胞，CD8 T细胞和巨噬细胞相关。签名也与TMB评分有关，它可能对评估免疫疗法的功效有影响。结论：这是kirc的第一个与科学家族相关签名，我们证明了其有效性。它在预测kirc患者的预后起着重要作用。它还有可能成为指导临床实践中脊髓癌免疫疗法的强大工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号